Making nursery admissions easier to giving gold coins: Indian cities’ push for COVID-19 vaccination
Only 39% of total population has received both doses of COVID-19 vaccine in India
Omicron in southern Africa: Zimbabwe tries to pull all stops
The country recorded 4,367 new cases December 14, 2021
Serum Institute’s COVID-19 vaccine up for emergency approval
Civil society organisations urge Indian drug regulator to put vaccine trial data in public domain
Inconvenient truth: Why omicron emerged, and why it could have been avoided
Best bet to tide over current crisis remains what we have known since the beginning of pandemic: Treat vaccine hesitancy and vaccine nationalism, …
Covishield, Covaxin may work against ‘double mutant’
ICMR, CCMB assurance can be a boon amid rising prevalence of B.1.617
Coronavirus update: Centre offers free foodgrain amid collapsing healthcare system
Modi government announces 5 kg foodgrain per head a month for 2 months
COVID-19: First few peer reviewed studies suggest vaccine induced antibodies fail to protect from Omicron
The studies, published in Nature, covered Oxford-AstraZeneca vaccine, but not India’s indigenous Covaxin
COVID-19 vaccines for all: India’s supply story deconstructed
Vaccination presents a way out of the COVID-19 mess India has landed in; but jabs are in short supply and there’s no clarity …
Lateral Thoughts: The uncomfortable science of booster vaccine
The disjoint between research and policy has never been so evident than in the case of vaccine boosters
The fading mirage of a TRIPS waiver
A year later, the proposal to lift WTO’s intellectual property blocks to making COVID vaccines has not inched forward
Simply Put: Magic box of COVID-19 vaccines
COVID-19 is already endemic, lack of data plagues understanding about vaccine efficacy: Gagandeep Kang
Gagandeep Kang, ex-officio member of a working group on COVID-19 vaccines at the WHO, talks to DTE on vaccines, their effectiveness and urgent …
COVID vaccines: How to make sense of reports on their effectiveness
Real-world trials come with some problems: The target of vaccination, what time it was rolled out and emerging variants
Early human trial of COVID-19 vaccine gives positive results
Developed by Beijing-based firm, the vaccine shows development of both forms of immunity
A week of arrogance and distrust
An interdependent world can’t be an inequitable world. We are seriously off track on many counts, writes Sunita Narain
Everyone DOESN’T need booster jabs of COVID-19 vaccines: Lancet study (but are the rich countries reading?)
Access to vaccination has been vastly inequal; Booster doses in developed countries will further squeeze out low, mid-income …
TRIPS waiver for COVID-19 vaccines, meds just got tougher after US support
Biden administration wants text-based negotiations on a waiver limited to vaccines but no one is complaining
SARS-CoV-2 changes classic feature of virus becoming endemic: Shahid Jameel
Shahid Jameel, former head of the Indian SARS-CoV-2 Genomics Consortium, speaks to DTE about how a virus mutates, the trajectory of COVID-19,…
COVID-19: Trump’s promise fuels anti-vaxx movement
Anti-vaccine theories inspire fear in the general population, undermining a coordinated effort to defeat the virus
No COVID-19 vaccine before 2021, Centre puts out then deletes
Sentence in question inadvertently included: PIB official; Things are contextual, says author of original article
‘Compromise’ on TRIPS waiver is a sellout
Tough new conditions emerge in the compromise deal to ease WTO intellectual property barriers to production of COVID-19 medical tools
The curious case of Covaxin royalties
ICMR’s contradictions and obfuscation on ownership of the vaccine’s intellectual property is not helping in the fight against COVID-…
COVID-19 Challenge 2021: How does the world overcome vaccine shortage
The pharmaceuticals industry must come together to ensure all adults are vaccinated against the novel coronavirus; …
COVID-19 in Africa: The pain of getting the jab
The COVAX Facility and the African Union are struggling to bring some relief to Africa which has been suffering from vaccine apartheid
Phase 1 human trials of Oxford University encouraging: Lancet
The sample size will have to be expanded across demography to check safety and efficacy